


## Soticlestat

Cat. No.:	HY-109123
CAS No.:	1429505-03-2
Molecular Formula:	C <sub>23</sub> H <sub>23</sub> N <sub>3</sub> O <sub>2</sub>
Molecular Weight:	373.45
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the COA.



### BIOLOGICAL ACTIVITY

#### Description

Soticlestat (TAK-935;OV935) is a potent, selective, orally active and first-in-class **cholesterol 24-hydroxylase** inhibitor. Soticlestat has the potential for epilepsy syndromes research<sup>[1][2]</sup>.

#### In Vitro

Cholesterol 24-hydroxylase (CH24H) is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by Soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity<sup>[2]</sup>.

### REFERENCES

- [1]. Krista Eschbach, et al. Stiripentol for the treatment of seizures in Dravet syndrome. *Expert Rev Clin Pharmacol*. 2019 May;12(5):379-388.
- [2]. Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome. August 25, 2020.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA